Director, Functional Genomics
AstraZeneca, United Kingdom
Ceri Wiggins (PhD) is Director of Phenotypic Screening in the Functional Genomics department at AstraZeneca, where her group is responsible for identifying novel targets to support AstraZeneca’s clinical pipeline. Prior to AZ, Ceri spent 9 years at Horizon Discovery where she lead their R&D team in the development of Horizon’s CRISPR screening platform and internal target discovery initiative. She also led the scientific development and commercialisation of Horizon’s novel base editing platform Pinpoint™.